Analyst Ratings For Corbus Pharmaceuticals (NASDAQ:CRBP)
Today, Raymond James Financial initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform with a price target of $24.00.
Some recent analyst ratings include
- 1/19/2018-Raymond James Financial initiated coverage with a Outperform rating.
- 12/29/2017-Noble Financial Reiterated Rating of Buy.
- 4/3/2017-JMP Securities Reiterated Rating of Outperform.
- 11/30/2016-Aegis Reiterated Rating of Buy.
Recent Insider Trading Activity For Corbus Pharmaceuticals (NASDAQ:CRBP)
Corbus Pharmaceuticals (NASDAQ:CRBP) has insider ownership of 11.90% and institutional ownership of 27.47%.
- On 11/15/2017 David P Hochman, Director, bought 5,000 with an average share price of $6.55 per share and the total transaction amounting to $32,750.00.
- On 11/13/2017 David P Hochman, Director, bought 5,000 with an average share price of $6.90 per share and the total transaction amounting to $34,500.00.
- On 11/10/2017 Barbara White, Insider, bought 2,836 with an average share price of $7.00 per share and the total transaction amounting to $19,852.00.
- On 11/10/2017 David P Hochman, Director, bought 10,000 with an average share price of $7.08 per share and the total transaction amounting to $70,800.00.
- On 11/10/2017 Sean F Moran, CFO, bought 1,500 with an average share price of $7.04 per share and the total transaction amounting to $10,560.00.
- On 11/10/2017 Yuval Cohen, CEO, bought 1,000 with an average share price of $7.17 per share and the total transaction amounting to $7,170.00.
- On 8/11/2017 Barbara White, Insider, bought 2,479 with an average share price of $6.05 per share and the total transaction amounting to $14,997.95.
Recent Trading Activity for Corbus Pharmaceuticals (NASDAQ:CRBP)
Shares of Corbus Pharmaceuticals closed the previous trading session at 8.30 up +0.35 4.40% with 532859 shares trading hands.
